Visiting Dana-Farber? See our prescreening and mask requirements.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Each patient's care combines the finest treatments currently available for Waldenström's macroglobulinemia with innovative new therapies based on research discovered through the collaboration of the center's laboratories and many other scientists from around the world.
The Bing Center for Waldenström's Macroglobulinemia offers patients access to a wide range of clinical research trials. The main goal of clinical research at the Bing Center for Waldenström's Macroglobulinemia is to swiftly and efficiently take discoveries made in the laboratory to the clinic, where they can benefit the health and well-being of the patient.
This includes studies aimed at improving the outcomes of patients undergoing biological therapies using agents in trials such as Rituxan and bortezomib that attempt to kill Waldenström's macroglobulinemia tumor cells directly. The center also has clinical research trials evaluating supportive therapies like statins and phosphodiesterase inhibitors to help understand the mechanics of the disease.
21-622: A phase 2 study evaluating loncastuximab tesirine in patients with previously treated Waldenström Macroglobulinemia Principal Investigator: Shayna Sarosiek, MD
21-439: A phase 2 study on acalabrutinib and anti-CD20 antibody in patients with anti-MAG mediated neuropathy Principal Investigator: Jorge Castillo, MD
New Patient Appointments 877-442-3324
Clinical Trials Questions?
877-DF-TRIAL (877-338-7425)